846023-55-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Methoxy-3-(3-(4-Methylpiperazin-1-yl)propoxy)aniline is used as a drug development compound for its potential as a serotonin receptor antagonist, which aids in the treatment of certain neurological disorders and mental health conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-MP-3 is used as a precursor in the synthesis of various pharmaceutical compounds, contributing to the creation of new therapeutic agents.
Used in Research and Development:
4-Methoxy-3-(3-(4-Methylpiperazin-1-yl)propoxy)aniline is utilized in research settings to explore its properties and potential applications further, including its role in the treatment of specific conditions and its interaction with biological systems.

Upstream product

• 846023-54-9 1-[3-(2-methoxy-5-nitrophenoxy)propyl]-4-methylpiperazine 
• 92878-95-0 1-(2-methoxy-5-nitrophenoxy)-3-chloropropane 
• 109-01-3 1-methyl-piperazine 
• 636-93-1 5-nitroguaiacol 

Downstream Products

• 846023-56-1 2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-{4-methoxy-3-[3-(4-methylpiperazin-1-yl)-propoxy]-phenylamino}-acrylamide 
• 380843-75-4 bosutinib 

Relevant academic research and scientific papers

Method for preparing bosutinib intermediate

The invention provides a method for preparing a bosutinib intermediate. The method comprises the following steps: A, adding SM-1, 1-bromo-3-chloropropane and an acid-binding agent into a reaction solvent, controlling the temperature until the reaction is

A robust, streamlined approach to bosutinib monohydrate

This article describes a systematic approach used to streamline the process for the isolation of bosutinib monohydrate, a promiscuous solvate former. A thorough understanding of the complex solid form landscape was garnered, and this knowledge was used to

PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS

Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.

Process for preparation of 4-amino-3-quinolinecarbonitriles

This invention discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile comprising combining an amine compound with a cyanoacetic acid and an acid catalyst to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline in an alcoholic solvent and a trialkylorthoformate to yield a 3-amino-2-cyanoacrylamide; combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride in acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 4-amino-3-quinolinecarbonitrile and also discloses a process for the preparation of a 7-amino-thieno[3,2-b]pyridine-6-carbonitrile comprising combining a disubstituted 3-amino thiophene with a cyanoacetamide and trialkylorthoformate in an alcoholic solvent to obtain a 3-amino-2-cyanoacrylamide; and combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride and acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 7-amino-thieno[3,2-b]pyridine-6-carbonitrile and also discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile by combining an amine compound with a cyanoacetic acid and a peptide coupling reagent to obtain a suspension; filtering the suspension to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline, an alcoholic solvent, and triethylorthoformate to yield a 3-amino-2-cyanoacrylamide; and combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride to yield a 4-amino-3-quinolinecarbonitrile.